Skip to main content
Signal8

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

$IRONPress releaseNov 5, 2026, 8:30 AM ET

Disc Medicine's pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints, reducing whole-blood metal-free PPIX by 41.4% versus placebo and adding 12.2 hours of monthly pain-free light exposure. The company plans to resubmit the bitopertin NDA by end of 2026, with an FDA decision anticipated by mid-2027, and will announce selcodebart pivotal plans in anemia of myelofibrosis after an end-of-Phase 2 FDA meeting. Disc ended Q3 with $682.8 million in cash and securities, and an October offering adding $485.9 million net proceeds extends the runway into 2030, funding the anticipated bitopertin launch.

Key figures

Drug Name
bitopertin
Guidance
Bitopertin NDA resubmission by end of 2026; FDA decision anticipated by mid-2027; end-of-Phase 2 FDA meeting feedback on selcodebart in anemia of MF by year-end
Phase Of Trial
Phase 3
Cash runway
into 2030
Net loss q3
59500000
Cash position
682800000
Rnd expense q3
44100000
Sga expense q3
20100000
Pix reduction vs placebo
41.4%
Light tolerance gain hours
12.2
October offering net proceeds
485900000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.